Welcome to our dedicated page for THERMA BRIGHT news (Ticker: TBRIF), a resource for investors and traders seeking the latest updates and insights on THERMA BRIGHT stock.
Therma Bright Inc. reports developments as a developer and investment partner in advanced diagnostic and medical device technologies. Recurring updates center on commercialization of the Venowave™ mobile compression device, including distribution relationships, follow-on unit orders, and use cases in vascular care, post-surgical recovery, circulation support, and DVT prevention.
The company also issues portfolio updates involving Inretio’s PREVA™ Neuro-Thrombectomy System and InStatin’s inhaled statin programs for respiratory disease. Other news categories include board changes, warrant-related capital actions, shareholder-meeting matters, and market expansion through U.S. healthcare distribution channels.
Therma Bright, a developer of diagnostic and medical device technologies, announces a non-brokered private placement offering up to $1,000,000 by issuing 100,000,000 units at $0.01 per unit. Each unit includes one common share and a half-warrant, with full warrants exercisable over three years at $0.05 in the first year and $0.10 in the subsequent years. The proceeds will fund their Digital Cough technology, pay debts, and support general working capital. The offering is expected to close by June 7, 2024, pending regulatory approvals. Additionally, Therma Bright has granted stock options and warrants to directors, officers, consultants, and entered into debt settlements issuing common shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.